Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-24T23:23:02.209Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors

Published online by Cambridge University Press:  25 June 2009

Luca Rozzini ,
Barbara Vicini Chilovi ,
Marta Conti ,
Erik Bertoletti ,
Marina Zanetti ,
Marco Trabucchi  and
Alessandro Padovani
Luca Rozzini*
Affiliation:
Department of Neurology, University of Brescia, Italy Geriatric Research Group, Brescia, Italy.
Barbara Vicini Chilovi
Affiliation:
Department of Neurology, University of Brescia, Italy Geriatric Research Group, Brescia, Italy.
Marta Conti
Affiliation:
Department of Neurology, University of Brescia, Italy
Erik Bertoletti
Affiliation:
Department of Neurology, University of Brescia, Italy
Marina Zanetti
Affiliation:
Department of Neurology, University of Brescia, Italy
Marco Trabucchi
Affiliation:
Geriatric Research Group, Brescia, Italy.
Alessandro Padovani
Affiliation:
Department of Neurology, University of Brescia, Italy
*
Correspondence should be addressed to: Luca Rozzini, MD, Department of Neurology, University of Brescia, Piazzale Spedali Civili 1, 25100 Brescia, Italy. Phone: +39 030 3995632; Fax: +39 030 3849205. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: This study examines the joint effect on cognition of selective serotonin re-uptake inhibitors (SSRIs) and cholinesterase inhibitors (AChEIs) in depressed patients affected by Alzheimer's disease (AD) living at home.

Methods: The study was conducted in two different outpatient neurological clinics. 338 patients with probable AD were treated with ChEis (donepezil, rivastigmine and galantamine) as per the clinician's judgment and were observed for nine months. At study entry, participants underwent a multidimensional assessment evaluating cognitive, functional and psychobehavioral domains. All patients were evaluated at baseline, after one (T1), three (T2) and nine months (T3). Patients were grouped in three different categories (patients not depressed and not treated with SSRIs, patients depressed and treated with SSRIs, and patients depressed but not treated with SSRIs).

Results: At baseline 182 were diagnosed as not depressed and not treated with SSRIs, 66 as depressed and treated with SSRIs, and 90 as depressed but not treated with SSRIs. The mean change in MMSE score from baseline to nine months showed that depressed patients not treated worsened in comparison with those not depressed and not treated with SSRIs (mean change −0.8 ± 2.3 vs 0.04 ± 2.9; p = 0.02) and patients depressed and treated with SSRI (mean change −0.8 ± 2.3 vs 0.1 ± 2.5; p = 0.03).

Conclusions: In AD patients treated with AChEIs, SSRIs may exert some degree of protection against the negative effects of depression on cognition.

Keywords

Alzheimer diseasedepressioncholinesterase inhibitorsSSRI
Type
Research Article
Information
International Psychogeriatrics , Volume 22 , Issue 1 , February 2010 , pp. 114 - 119
Copyright
Copyright © International Psychogeriatric Association 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.Google Scholar
Bellelli, G. et al. (2005). Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the “real world” (CRONOS project): a 36-week follow-up study. Aging – Clinical and Experimental Research, 17, 54–61.CrossRefGoogle Scholar
Blazer, D., Hughes, D. C. and George, L. K. (1987). The epidemiology of depression in an elderly community population. Gerontologist, 27, 281–287.CrossRefGoogle Scholar
Bruce, M. L., Seeman, T. E., Merrill, S. S. and Blazer, D. G. (1994). The impact of depressive symptomatology on physical disability: MacArthur Studies of Successful Aging. American Journal of Public Health, 84, 1796–1799.CrossRefGoogle ScholarPubMed
Cassano, G. B., Puca, F., Scapicchio, P. L. and Trabucchi, M. (2002). Italian Study Group on Depression in Elderly Patients: paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Journal of Clinical Psychiatry, 63, 396–402.CrossRefGoogle Scholar
Constant, E. L. et al. (2005). Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depression and Anxiety, 21, 78–89.CrossRefGoogle ScholarPubMed
Cummings, J. L. et al. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314.CrossRefGoogle ScholarPubMed
Fioravanti, M. et al. (1994). The Italian version of the Alzheimer's Disease Assessment Scale, ADAS: psychometric and normative characteristics from a normal aged population. Archives of Gerontology and Geriatrics, 19, 21–30.CrossRefGoogle ScholarPubMed
Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.CrossRefGoogle ScholarPubMed
Harmer, C. J., Bhagwagar, Z., Cowen, P. J. and Goodwin, G. M. (2002). Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology, 163, 106–110.CrossRefGoogle ScholarPubMed
Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. and Martin, R. L. (1982). A new clinical scale for the staging of dementia. British Journal of Psychiatry, 140, 566–572.CrossRefGoogle ScholarPubMed
Kalayam, B. and Alexopoulos, G. S. (1999). Prefrontal dysfunction and treatment response in geriatric depression. Archives of General Psychiatry, 56, 713–718.CrossRefGoogle ScholarPubMed
Katz, S., Downs, T. D., Cash, H. R. and Grotz, R. C. (1970). Progress in development of the index of ADL. Gerontologist, 10, 20–30.CrossRefGoogle ScholarPubMed
Lawton, M. P. and Brody, E. M. (1969). Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist, 9, 179–186.CrossRefGoogle ScholarPubMed
Levkovitz, Y. et al. (2002). The SSRI drug fluoxetine, but not the noradrenergic tricyclic drug desipramine, improves memory performance during acute major expression. Brain Research Bulletin, 58, 345–350CrossRefGoogle Scholar
McKhann, G. et al. (1984). Clinical diagnosis of Alzheimer's disease. Report of the NINCDS–ADRDA work group under the auspices of the Department of Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–944.CrossRefGoogle ScholarPubMed
Morse, L. J., Payton, S. M., Cuny, G. D. and Rogers, J. T. (2004). FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. Journal of Molecular Neuroscience, 24, 129–136.CrossRefGoogle Scholar
Niederehe, G., Burt, D. B. and Zembar, M. J. (1995). Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychological Bulletin, 117, 285–305.Google Scholar
Pákáski, M. et al. (2005). Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochemistry International, 47, 190–195.CrossRefGoogle ScholarPubMed
Pelton, G. H. et al. (2008). Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. International Journal of Geriatric Psychiatry, 23, 670–676.CrossRefGoogle ScholarPubMed
Rapaport, M. H., Schneider, L. S., Dunner, D. L., Davies, J. T. and Pitts, C. D. (2003). Efficacy of controlled- release paroxetine in the treatment of late-life depression. Journal of Clinical Psychiatry, 64, 1065–1074.CrossRefGoogle ScholarPubMed
Rocca, P. et al. (2005). Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. Journal of Clinical Psychiatry, 66, 360–369.CrossRefGoogle ScholarPubMed
Rozzini, L., Vicini Chilovi, B., Bellelli, G., Bertoletti, E., Trabucchi, M. and Padovani, A. (2005). Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy. International Journal of Geriatric Psychiatry, 20, 547–551.CrossRefGoogle ScholarPubMed
Rozzini, L., Vicini Chilovi, B., Bertoletti, E., Trabucchi, M. and Padovani, A. (2007). Acetylcholinesterase inhibitors and depressive symptoms in patients with mild to moderate Alzheimer's disease. Aging Clinical Experimantal Research, 19, 220–223.CrossRefGoogle ScholarPubMed
Savaskan, E., Müller, S. E., Böhringer, A., Schulz, A. and Schächinger, H. (2007). Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients. International Journal of Neuropsychopharmacology, 13, 1–8.Google Scholar
Sheikh, J. I. and Yesavage, J. A. (1986). Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In Brink, T. L. (ed.), Clinical Gerontology: A Guide to Assessment and Intervention (pp. 165–173). New York: The Haworth PressGoogle Scholar
SPSS (2002). Statistical Package for the Social Sciences for Windows Release 11.5.1 (Italian version). Chicago: SPSS Inc.Google Scholar
Suh, G. H. and Shah, A. (2001). A review of the epidemiological transition in dementia: cross-national comparison of the indices related to Alzheimer's disease and vascular dementia. Acta Psychiatrica Scandinavica, 104, 4–11.CrossRefGoogle ScholarPubMed
Vythilingam, M. et al. (2004). Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biological Psychiatry, 56, 101–112.CrossRefGoogle ScholarPubMed